Table 2.

Clinical characteristics and chimerism data in intestinal transplant recipients with and without early (<3 months) moderate to severe rejection

	Moderate to severe rejection (n=4)	Mild or no rejection (n=5)	p value
Recipient Age	21.8 ± 21.5	30.6 ± 22.2	ns
Donor Age	13.3± 23.2	17.4 ± 16.4	ns
Multivisceral Allograft	1/4	3/5	ns
Pre-Tx PRA>0 (CDC)	1/4	0/5	ns
Pre-Tx DSA (SPA)	1/4	1/5	ns
Cumulative ATG induction dose (mg/kg)	8.0 ± 1.5	9.9 ± 1.4	ns
Mean tacrolimus T0 levels [0–3 mo] (ng/mL)	15.3 ± 2.1	16.8 ± 3.2	ns
De novo DSA (SPA)	3/4	0/5	p<0.05
GVHD	0/4	1/5	ns
T-cell macrochimerism	3/4	5/5	ns
B-cell macrochimerism	1/4	3/5	ns
Myeloid macrochimerism	0/4	3/5	ns
Median [range] duration of T-cell macrochimerism (days)	28.5 [0–58]	127 [21–378]	p=0.19
Median [range] peak of CD3 chim. (days × %)	2.6 [0–3.3]	16.3 [6.6–43.1]	p<0.02
Median [range] peak of CD4 chim. (days × %)	4.8 [0–7.8]	10.3 [8.3–29.4]	p<0.02
Median [range] peak of CD8 chim. (days × %)	1.8 [0–3.7]	21.4 [6.8–54.8]	p<0.02
Median [range] peak of CD19 chim. (days × %)	0 [0–0]	8.8 [0–61]	p=0.11
Median [range] peak of CD33 chim. (days × %)	0 [0–0]	0 [0–7.1]	ns
Median [range] peak of CD11c chim. (days × %)	0 [0–0]	0 [0–12.6]	ns
Median [range] peak of CD14 chim. (days × %)	0 [0–0]	0 [0–1.4]	ns
Median [range] CD3 chim. AUC (days × %)	34.5 [0–62]	820 [101–9098]	p<0.02
Median [range] CD4 chim. AUC (days × %)	69.5 [0–225]	750 [142–7653]	p<0.05
Median [range] CD8 chim. AUC (days × %)	24.7 [0–69]	921 [105–8109]	p<0.02
Median [range] CD19 chim. AUC (days × %)	0 [0–0]	165 [0–9157]	ns
Median [range] Myeloid chim. AUC (days × %)	0 [0–0]	202 [0–731]	ns
Median follow-up (days [range])	415 [132–941]	524 [343–991]	ns
Death	0/4	2/5	ns

Abbreviations: ATG, anti-thymoglobulin; AUC, Area Under the Curve; CDC, complement-dependent cytotoxicity; chim., chimerism; DSA, donor-specific antibody; GVHD, graft-vs-host disease; mo, months; PRA, panel reactive antibody; Pre-Tx, pre-transplantation; SPA, solid-phase assay; T0, trough levels